Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy.

Li, Qingfang; Li, Zhihui; Luo, Ting; Shi, Huashan

Li, Qingfang; Li, Zhihui; Luo, Ting; Shi, Huashan.

Afiliación

Li Q; Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, West China Hospital, National Clinical Research Center for Geriatrics, Sichuan University, Chengdu, China.
Li Z; Department of Oncology, The General Hospital of Western Theater Command, Chengdu, PR China.
Luo T; Department of Breast, Cancer Center, West China Hospital, Sichuan University, 610041, Chengdu, P. R. China. luoting@wchscu.cn.
Shi H; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, 610041, Chengdu, P. R. China. shihuashan@scu.edu.cn.

Mol Biomed ; 3(1): 47, 2022 Dec 21.

Article en En | MEDLINE | ID: mdl-36539659

Palabras clave

Cancer therapy; Combination inhibitor; PI3K/AKT/mTOR; RAF/MEK/ERK; Small molecular inhibitors

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Mol Biomed Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Singapur

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google